Study to Assess the Safety, Tolerability and Pharmacokinetics After Multiple Doses of AZD2066 in Japanese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

September 30, 2008

Study Completion Date

July 31, 2009

Conditions
Healthy
Interventions
DRUG

AZD2066

Oral solution administered orally once per day on day 1, and then day 3 through to day 12 for the first and second dose panels and day 5 through to day 14 for the third and fourth dose panels. For the fifth and sixth panels, oral solution administered once per day on day 1, and then day 5 through to day 16. Specific dose depends on dose panel.

DRUG

Placebo

Oral solution administered orally once per day on day 1, and then day 3 through to day 12 for the first and second dose panels and day 5 through to day 14 for the third and fourth dose panels. For the fifth and sixth panels, oral solution administered once per day on day 1, and then day 5 through to day 16.

Trial Locations (1)

Unknown

Research SIte, Fukuoka

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY